Sonia Veluchamy
As CEO and Co-Founder of Celegence, Sonia Veluchamy is passionate about helping Life Sciences companies to navigate complex regulatory requirements so that they can achieve both, greater efficiency, and reduced time to market. Sonia was the Managing Director and a Board member of Aris Global, a global drug safety and regulatory software company. Sonia brings depth of industry knowledge and significant technology services management experience to Soterius.
Disclaimer
Copyright 2025 by Soterius, Inc. All rights reserved. Soterius logo are trademarks or registered trademarks of Soterius in all jurisdictions. Other marks may be trademarks or registered trademarks of their respective owners. The information you see, hear or read on the pages within this presentation, as well as the presentation’s form and substance, are subject to copyright protection. In no event, may you use, distribute, copy, reproduce, modify, distort, or transmit the information or any of its elements, such as text, images or concepts, without the prior written permission of Soterius. No license or right pertaining to any of these trademarks shall be granted without the written permission of Soterius (and any of its global offices and/or affiliates). Soterius reserves the right to legally enforce any infringement of its intellectual property, copyright and trademark rights. Any content presented herewith should only be considered for general informational purposes and should not be considered as specific to the requirements of any particular organisation or for any specific purpose. Soterius does not make any representations or warranties about the completeness, reliability, appropriateness, relevance, or accuracy of the content presented here.
Discover more
admin •
10 Min Read
Medication Errors & Patient Safety – Part I
Why Medication Errors Matter More Than We Think Medication errors are a significant public health concern, often occurring during various stages of care, whether preventive, diagnostic, therapeutic, or rehabilitative. These…
admin •
10 Min Read
Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV
Legal Framework of PADE Inspections Good Corrective Action Plan - Four Reasons to Submit a Complete and Timely Written Response May be considered in an FDA compliance decision. Demonstrates your…
admin •
10 Min Read
Post marketing Adverse Drug Experience (PADE) Inspections – Part III
Legal Framework of PADE Inspections Scientific Literature Reports Determine: If the firm reviews scientific literature and the frequency of the review. If the applicant or non-applicant is submitting expedited ICSRs…